|Publication number||USRE34069 E|
|Application number||US 07/481,572|
|Publication date||15 Sep 1992|
|Filing date||16 Feb 1990|
|Priority date||18 Aug 1983|
|Publication number||07481572, 481572, US RE34069 E, US RE34069E, US-E-RE34069, USRE34069 E, USRE34069E|
|Inventors||Hubert Koster, Nanda D. Sinha|
|Original Assignee||Biosyntech Gmbh|
|Export Citation||BiBTeX, EndNote, RefMan|
|Patent Citations (13), Non-Patent Citations (19), Referenced by (177), Classifications (8), Legal Events (11)|
|External Links: USPTO, USPTO Assignment, Espacenet|
--NR2 4 ( VIII)
--NR2 4 (VIII)
The invention relates to a process for the preparation of oligonucleotides of the general formula I indicated in claim 1. The oligonucleotides prepared according to the invention have defined sequences and can be used as specific primers and probes and are of great importance for the synthesis of complete genes (Arzneimittelforschung 30, 3a, 548, (1980)).
According to the most recent state of the art, oligonucleotides are prepared by either the phosphate or phosphite triester method using polymeric carriers (Nachr. Chem. Tech. Lab. 29, 230 (1981)). In order to be able to construct defined sequences, it is necessary for the individual units (nucleoside or nucleotides) to be provided with suitable protective groups. In this context, base-labile acyl groups are generally used for the protection of the exocyclic amino groups on the heterocyclic nucleobases, and a base-labile ester bond is used to attach the oligonucleotide chain to the polymeric carrier in a customary manner, and acid-labile trityl ether groups are used to protect the primary 5'--OH group. The phosphate protective group used in the phosphate triester method is customarily either the 2-chlorophenyl or the 4-chlorophenyl group, with an ester-type bond, which can only be removed by attack of a base or a nucleophile on the phosphorus atom. This type of step is inherently undesirable since it involves the risk of cleavage of the internucleotide phosphate ester bond. This risk has been greatly reduced by the use of oximate anions (Tetrahedron Lett. 19, 2727 (1978)), although these also attack the phosphorus atom in an undesired manner in the crucial step and, moreover, have the disadvantage that a relatively small amount of desired oligonucleotide is contaminated with every large amounts of involatile salts which are difficult to extract. This not only makes the working up and subsequent purification of the synthesized oligonucleotide difficult but also leads to considerable material losses.
In the phosphite triester method, the methyl group with an ester-type bond is customarily used as the phosphate protective group which can be removed by attack of a nucleophile on the methyl C atom (J. Amer. Chem. Soc. 99, 3526 (I1977)). Since attack on the P atom is avoided, there is likewise avoidance of the risk of cleavage of the internucleotide bond. The nucleophile customarily used is thiophenol/triethylamine, which are unpleasant to manipulate and, moreover, lead to involatile compounds which are difficult to extract and which, as mentioned above, both make work-up difficult and lead to considerable material losses.
Although the actual synthesis of oligonucleotides by the solid phase/phosphite or phosphate triester method takes place very efficiently and rapidly, the preparation of oligonucleotides of defined sequence remains very time-consuming. This is primarily due to the problems of the subsequent work-up and purification which take up a multiple of the actual synthesis time. The process of the invention operates at this point and provides in this connection a crucial technical improvement.
In order to obtain compounds of the formula I indicated in claim 1, ##STR2## in which B denotes a nucleobase, for example adenine (A), guanine (G), cytosine (C), thymine (T) or uracil (U) or their analogs, and R1 denotes hydrogen, hydroxyl or hydroxyl which is protected by the protective groups customary in nucleotide chemistry, and n denotes an integer from 1 to 200, according to the invention a variety of defined reaction steps are carried out, as follows:
(a) Reaction of a nucleoside of the general formula II. ##STR3##
R1 of the general formula II can be hydrogen; in this case the compounds of the formula I are oligodeoxynucleotides. The group R1 can also be hydroxyl or hydroxyl which is, where appropriate, protected by the protective groups customary in nucleotide chemistry. Examples of protective groups of this type are trityl, monomethoxytrityl and dimethoxytrityl, acyl, for example acetyl, benzoyl; tetrahydropyranyl, methoxytetrahydropyranyl, o-nitrobenzyl and silyl ethers, such as, for example, t-butyldiphenylsilyl ethers. A general review of the protective groups customary in nucleotide chemistry is to be found in, for example, Tetrahedron 1981, pages 363-369, Liebigs Ann. Chem. 1978, 839-850, and Nucleic Acids Research, Symposium Series No. 7, 1980, 39-59.
R2 is likewise a protective group customary in nucleotide chemistry according to the above mentioned publications, preferably the acid-labile 4,4'-dimethoxytrityl or 4,4',4"-trimethoxytrityl group. B' can likewise have a protective group customary in nucleotide chemistry according to the above mentioned prior publications.
The nucleoside of the formula II is reacted according to the invention with a phosphine derivative of the general formula III according to claim 1. ##STR4##
In the general formula, X denotes chlorine, bromine, CN or SCN; L denotes chlorine, bromine, CN, SCN or an amino radical of the formula--NR2 4 (formula VIII), where the groups R4 denote primary, or secondary or tertiary alkyl radicals having 1-10 carbon atoms, or together denote a cycloalkyl radical having 5-7 carbon atoms, optionally with alkyl branches, and/or can contain one or two nitrogen, oxygen and/or sulfur atoms as heteroatoms. The group L can also form a reactive heterocyclic radical, the imidazolyl, triazolyl, tetrazolyl, 3-nitro-1,2,4-triazolyl, thiazolyl, pyrrolyl, benzotriazolyl (optionally with substituents in the phenyl moiety) or benzohydroxytriazolyl (optionally with substituents in the phenyl ring) and the like.
R3 is the phosphine derivative of the general formula (III) is, according to the invention, a group of the general formula VII, ##STR5## which can be removed with the aid of bases by β-elimination and in which Y denotes hydrogen, methyl or ethyl. Z represents an electron-attracting group, for example, halogen, such as fluorine, chlorine or bromine, CN or NO2. Z can also denote phenyl, phenylthio, phenylsulfoxy or phenylsulfonyl, it being possible for the phenyl radicals to be substituted in the o,o'-position and/or p-position with halogen, CN or NO2. It is also possible for one of the groups CF3, CCl3 or CBr3 to replace the group ##STR6##
The reaction according to step a takes place in the presence of an organic base.
(b) Reaction of the nucleoside-.[.phosphorous.]. .Iadd.phosphorus .Iaddend.acid derivative, of the formula IV, obtained in step a. ##STR7##
The reaction of the compound according to formula IV is carried out with a nucleoside of the general formula V according to claim 1, which is bound to a polymeric carrier. ##STR8## It is possible to use soluble or insoluble, that is to say crosslinked, polymeric carriers, for example modified silica gel, glass, especially "controlled pore glass", polyester, polyamide, polyvinyl alcohol, polysiloxane, polystyrene or the like. Ester bonds are suitable and preferred for the attachment between the carrier and the nucleoside, including those derived from the levulinyl or β-benzoylpropionyl radical; the latter ester bonds can be cleaved with hydrazine under neutral conditions. The acid-labile trityl ether bond, optionally with substituents in the phenyl rings, is also suitable as a method of attachment, compare Liebigs Ann. Chem. 1974, 959.
(c) Oxidation of the carrier-bond nucleotide-nucleoside, of the general formula VI, obtained in step b. ##STR9##
Oxidation leads to a phosphate group; this can be carried out with, for example, iodine/H2 O, H2 O2 or organic peracids or, in general, by oxidation by introduction of O, S or Se.
(d) Blocking of free primary 5'--OH groups which have not been reacted in the reaction according to step b (in the product of the formula V).
These free hydroxyl groups are blocked with a permanent protective group, for example by reaction with acetic anhydride.
(e) Elimination of the protective groups(s) R2.
The elimination is carried out using, for example, a protonic acid or Lewis acid, such as ZnBr2 or dialkylaltuminum chloride, when R2 represents a trityl group or a methoxy derivative thereof.
(f) Introduction of further nucleoside phosphate or oligonucleoside phosphate units.
Steps a-e can be repeated to introduce at least one nucleoside phosphate moiety. Of course, when oligonucleoside phosphate units are employed, the chains are lengthened by more than one nucleoside phosphate unit.
(g) Elimination of all protective groups.
This elimination can be carried out in such a manner that, using aqueous ammonia, in one step the N-acyl groups on the heterocyclic bases, the ester bond between the oligonucleotide and the carrier (the latter can, where appropriate, also be cleaved with hydrazine under neutral conditions) an the phosphate protective group are eliminated by β-elimination in accordance with the general scheme 1 at the end of the description. An oligonucleotide having only a 5'-terminal trityl protective group is then obtained, and this can be purified directly in a manner known per se, after removal of the volatile base (ammonia), by high-pressure liquid chromatography (HPLC) on reverse phase material.
The intermediates of the general formula IV according to claim 1 are new compounds. They are in the form of very stable compounds which can be prepared in the pure form and are easy to manipulate but nevertheless are very reactive in the sense of forming internucleotide bonds. The use of R3 as a protective group which can be removed by bases via β-elimination makes is possible for the first time to eliminate all the protective groups, apart from the 5'-trityl group, in one step where, in an advantageous manner, by the use of volatile bases the desired oligonucleotide is contaminated with foreign materials to only a very small extent and thus directly afterwards can be purified by reverse phase HPLC due to the hydrophobic 5'-trityl group which is still present.
A further advantage of the process of the invention results from the fact that, due to the removal of the protective group by β-elimination, no attack on the P-atom takes place and thus none of the newly formed internucleotide bonds can be cleaved during the deprotection. Thus, the process of the invention takes very much less time and leads to overall purer products than do the processes hitherto available.
The invention is illustrated in detail below by means of examples, the phosphine derivatives used being those in which R3 is a β-cyanoethyl group. Details of the reaction and physical characteristics of the compounds prepared can be seen in schemes 2 and 3, Table 1, and FIGS. 1-7 at the end of the description.
A general summary of the reaction can be seen in scheme 2.
Apart from some improvements, dichloro-β-cyanoethoxyphosphine (1) is prepared as in Can. J. Chem. 58, 2686 (1980):
300 ml of ether and 79.0 g (1 mol) of pyridine are added through a dropping funnel to 137.5 g (1.0 mol) of PCl3 in a three-neck flask; the mixture is cooled to -78° C. under argon. Then a solution of 71.0 g (1 mol) of β-cyanoethanol in 150 ml of dry ether is added dropwise over the course of 1 to 1.5 hours. The cooling bath is removed; stirring is continued at room temperature for a further 3 hours (where necessary, another 300 ml of ether are added in order to ensure better stirrability). The stirrer and dropping funnel are removed under argon; the mixture is stored at 0° C. overnight. The solid salts are removed under argon; the precipitate is washed twice with 75 ml of ether each time. The combined organic phases are concentrated in vacuo; the residue is finally distilled in vacuo; boiling point 70°-75° C./0.4 mm Hg.
A solution of 17.2 g (0.1 mol) of β-cyanoethyl phosphorodichloridite (1) in 60 ml of ether is added dropwise, over the course of 1 to 1.5 hours, to a solution of the N-trimethylsilylated secondary amine (0.1 mol) or secondary amine (0.2 mol) in 30 ml of ether at -20° C. under argon. After stirring at room temperature for 20 hours, the amine hydrochloride is removed; the remaining solution is concentrated. The residue is finally distilled in vacuo in a short-path distillation apparatus.
The physical properties of the compounds thus obtained are summarized in Table 1.
FIGS. 1a, 1b and 1c show 31 P NMR spectra of three different β-cyanoethyl phosphoramidochloridites.
The N-morpholine derivative is too unstable to heat for distillation to be possible. Nevertheless, the preparation is so pure that the residue can be used directly for the preparation of the activated nucleoside derivatives. The purity is usually greater than 95% according to the 31 P NMR spectra.
The preparation of the appropriately protected nucleoside β-cyanoethyl phosphoramidites can be seen in scheme 3.
The synthesis is analogy to Tetrahedron Lett. 22, 1859 (1981), with some improvements, provides good yields.
3.0 mmol of the N-protected 5'-dimethoxytritylated deoxynucleoside are dried azeotropically using THF/toluene, dissolved in 15 ml of dry THF, and 12.0 mmol of N,N,N-diisopropylethylamine are added. 6.0 mmol of the β-cyanoethyl phosphoramidochloridite are added dropwise to the solution under argon, with vigorous stirring, over the course of 2 minutes. After a short time (2 to 5 minutes), the amine hydrochloride precipitates out. The suspension is stirred for a further 30 to 40 minutes. The amine hydrochloride is filtered off under argon and thoroughly washed with dry THF (10 to 15 ml). The entire organic phase is concentrated and dissolved in argon-saturated ethyl acetate (100 ml). The organic phase is extracted twice with 50 ml each time of argon-saturated 10% aqueous sodium carbonate solution. The organic phases are dried with sodium sulfate and evaporated under reduced pressure to give a foam. The foam is dissolved in a little ethyl acetate or toluene and precipitated in n-hexane at -78° C. The activated nucleosides are stable for several months when stored at -20° C. under argon.
FIG. 2 shows the 31 P NMR spectrum of one of the activated deoxynucleosides.
100 mg of "controlled pore glass" (CPG) loaded with a total of 8 umol of N-isobutyryldeoxyguanine (compare Tetrahedron Lett. 24, 747 (1983)) are consecutively condensed with the 5'-dimethoxytritylated N-acylated β-cyanoethyl N,N-diisopropylphosphoramidites of the deoxynucleosides C, C, A, T, G, G and C, in each case 20 to 25 equivalents of the phosphoramidite in acetonitrile being activated with 75-80 equivalents of sublimed tetrazole. The condensations are complete within 30 minutes at the most; the coupling yield is greater than 94%. After each condensation, oxidation with I2 /H2 O and blocking of unreacted 5'--OH groups with acetic anhydride are carried out. Then the dimethoxytrityl group is eliminated either with 3% trichloroacetic acid in nitromethane/1% methanol or ZnBr2 /nitromethane/1% H2 O.
The overall yield of the protected octanucleotide at the end of all condensation steps is 55% based on carrier-bound deoxyguanosine.
Complete deprotection and cleavage off from the carrier is achieved in one step by reaction of the glass beads with concentrated aqueous ammonia (3 ml) at 50° C. for 16 hours. The glass beads are then thoroughly washed with 50% aqueous methanol (3 times with 3 ml each time). The liquid phase is removed by evaporation (removal of the methanol) and freeze-drying. Then an aliquot is filtered through a millipore filter and purified by HPLC or RP 18 as can be seen in FIG. 3.
The fractions which contain the 5'-dimethoxytritylated oligonucleotide are collected; the volatile buffer is removed in a rotary evaporator in vacuo, 1 ml of 80% strength acetic acid is added to the residue. After 45 minutes at room temperature, the acetic acid is removed by freeze-drying.
The material thus obtained is phosphorylated in the customary manner (Liebigs Ann. Chem. 1978, 982) with T4-polynucleotide kinase and γ-32 P-ATP. The resulting product is characterized by polyacrylamide gel electrophoresis comparing with a homo-oligo-dT chain length standard (Nucleic Acids Res. 6, 2096 (1979), FIG. 4) and by sequencing according to FIG. 5 (Liebigs Ann. Chem. 1978, 982).
FIGS. 6a to 6c show the results (HPLC, gel electrophoresis, sequencing) of the synthesis of d(GGGATCCC) using the nucleoside β-cyanoethyl N,N-dimethylphosphoramidites, FIGS. 6a to 6c show the results (HPLC, g, electrophoresis, sequencing) of the synthesis of d(GGGATATCCC) using the nucleoside β-cyanoethyl N,N-morpholinophosphoramidites.
The results given in FIGS. 3, 6a and 7a were obtained by using a gradient from 10 to 25 vol. % CH3 CN, 5 min, and 25 to 29 vol. % CH3 CN, 30 min, in 0.1M triethylammonium acetate at pH 7.0. ##STR10##
TABLE 1__________________________________________________________________________Physical data of β-cyanoethyl phosphoramidochloridites 3a 3b 3cCompound L = N,N-dimethylamino L = N,N-diisopropylamino L = N-morpholino__________________________________________________________________________Boiling point 90-92°/0.6 nm 103-5°/0.06 nm --Chemical shift.sup.(2) 175.97 ppm 179.82 ppm 168.22 ppmin 31 P NMR inCH3 CNChemical shift in 4.01, 4.17(2t, POCH2, 2H) 4.02, 4.2(2t, POCH2, 2H) 3.96, 4.1(2t, POCH2, 2H)1 H NMR in ppm 2.71(t, CH2CN, 2H) 3.8(m, N(CH)2, 2H) 3.67(t, O(CH2)2, 4H) 2.7(d, N(CH3)2, 6H) 2.77(t, CH2 CH, 2H) 3.17(m, PN(CH2)2, 4H) 1.29(d, NCH(CH3)2, 12H) 2.74(t, CH2CN 2, 2H) Mass spectrum ##STR11## ##STR12## (Cl), 136(C2 H6 N), 110 (Cl), 166(C3 H4 NO), (Cl), 152(C3 H4 NO), (C3 H4 NO) 136(C6 H14 N) 136(C4 H8 O)__________________________________________________________________________ .sup.(1) The crude product after removal of amine hydrochloride and compounds volatile under high vacuum at room temperature has a purity of 93-95% according to the 31 P NMR spectrum .sup.(2) The chemical shifts are determined in acetoned6 with 80% strength H3 PO4 as the external standard.
|Cited Patent||Filing date||Publication date||Applicant||Title|
|US4310662 *||26 Dec 1979||12 Jan 1982||Genentech, Inc.||Nucleosidic phosphorylating agent and methods|
|US4415732 *||27 Mar 1981||15 Nov 1983||University Patents, Inc.||Phosphoramidite compounds and processes|
|US4419509 *||24 Aug 1981||6 Dec 1983||Eli Lilly And Company||Process for de-cyanoethylating blocked nucleotides|
|US4458066 *||24 Mar 1981||3 Jul 1984||University Patents, Inc.||Process for preparing polynucleotides|
|US4476301 *||22 Jun 1982||9 Oct 1984||Centre National De La Recherche Scientifique||Oligonucleotides, a process for preparing the same and their application as mediators of the action of interferon|
|US4500707 *||16 Mar 1982||19 Feb 1985||University Patents, Inc.||Nucleosides useful in the preparation of polynucleotides|
|US4591614 *||30 Apr 1984||27 May 1986||The Johns Hopkins University||Preparation of oligodeoxyribonucleoside alkyl or arylphosphonates|
|US4605735 *||9 Feb 1984||12 Aug 1986||Wakunaga Seiyaku Kabushiki Kaisha||Oligonucleotide derivatives|
|EP0040099A1 *||12 May 1981||18 Nov 1981||ens BIO LOGICALS INC.||Polynucleotide synthesis|
|EP0061746A1 *||26 Mar 1982||6 Oct 1982||University Patents, Inc.||Phosphoramidite compounds and their use in producing oligonucleotides|
|EP0064796A2 *||10 May 1982||17 Nov 1982||Unilever N.V.||Phosphorylating agent and process for the phosphorylation of organic hydroxyl compounds|
|EP0090789A1 *||24 Mar 1983||5 Oct 1983||Monsanto Company||Chemical DNA synthesis|
|EP0131993A2 *||29 Jun 1984||23 Jan 1985||Stichting Katholieke Universiteit||Phosphorylating agent; a process for the preparation thereof; a process for phosphorylating an organic hydroxyl or amine compound|
|1||*||Beaucage and Caruthers (1981) Tet. Lett. 22:1859 1862.|
|2||Beaucage and Caruthers (1981) Tet. Lett. 22:1859-1862.|
|3||*||Caruthers, M. H., Science 230:281 (1985).|
|4||Clesen et al., "Tetrahedron Letters", vol. 25, No. 12, pp. 1307-1310, 1984.|
|5||*||Clesen et al., Tetrahedron Letters , vol. 25, No. 12, pp. 1307 1310, 1984.|
|6||*||Gao, X. et al. Nucleic Acids Research 13(2):573 (1985).|
|7||*||H. Koster et al., Nucleic Acids Research Symposium Series No. 7 (1980) pp. 39 61.|
|8||H. Koster et al., Nucleic Acids Research Symposium Series No. 7 (1980) pp. 39-61.|
|9||Lelsinger et al., "Jour. of the Amer. Chem. Soc." vol. 98, No. 12, Jun. 1976, pp. 3655-3661.|
|10||*||Lelsinger et al., Jour. of the Amer. Chem. Soc. vol. 98, No. 12, Jun. 1976, pp. 3655 3661.|
|11||Marugg et al., "Recl. Trav. Chim. Pays-Bas" vol. 103, pp. 97-98, 1984.|
|12||*||Marugg et al., Recl. Trav. Chim. Pays Bas vol. 103, pp. 97 98, 1984.|
|13||Narang, "Tetrahedron", vol. 39, No. 1, pp. 3-22, 1983.|
|14||*||Narang, Tetrahedron , vol. 39, No. 1, pp. 3 22, 1983.|
|15||*||Ogilvie, K. K. et al., Can J. Chem 58:2686 (1980).|
|16||*||Urdea, M. S. et al. Nucleic Acids Research Symposium Ser. 16 (1985) pp. 257 260.|
|17||Urdea, M. S. et al. Nucleic Acids Research Symposium Ser. 16 (1985) pp. 257-260.|
|18||*||V. Amarnath and A. D. Broom, Chemical Reviews 77(2)183 (1977).|
|19||*||Zon, G. et al., Nucleic Acids Research 13(22):8181 (1985).|
|Citing Patent||Filing date||Publication date||Applicant||Title|
|US5428149 *||14 Jun 1993||27 Jun 1995||Washington State University Research Foundation||Method for palladium catalyzed carbon-carbon coulping and products|
|US5510476 *||7 Jul 1994||23 Apr 1996||Isis Pharmaceuticals, Inc.||Carbocation scavenging during oligonucleotide synthesis|
|US5633361 *||21 Mar 1995||27 May 1997||Washington State University Research Foundation||Method for palladium catalyzed carbon-carbon coupling and products|
|US5714597 *||8 Mar 1996||3 Feb 1998||Isis Pharmaceuticals, Inc.||Use of carbocation scavenger during oligonucleotide synthesis|
|US5734041 *||20 Oct 1995||31 Mar 1998||Mcgill University||Preparation of chiral phosphorothioate oligomers|
|US5760209 *||3 Mar 1997||2 Jun 1998||Isis Pharmaceuticals, Inc.||Protecting group for synthesizing oligonucleotide analogs|
|US5783690 *||18 Sep 1997||21 Jul 1998||Isis Pharmaceuticals, Inc.||Protecting group for synthesizing oligonucleotide analogs|
|US5902881 *||3 Mar 1997||11 May 1999||Isis Pharmaceuticals, Inc.||Reagent useful for synthesizing sulfurized oligonucleotide analogs|
|US6147200||19 Aug 1999||14 Nov 2000||Isis Pharmaceuticals, Inc.||2'-O-acetamido modified monomers and oligomers|
|US6169177||6 Nov 1998||2 Jan 2001||Isis Pharmaceuticals, Inc.||Processes for the synthesis of oligomeric compounds|
|US6172217||27 Dec 1996||9 Jan 2001||Isis Pharmaceuticals Inc.||Method of synthesizing phosphorothioate oligonucleotides|
|US6207819||12 Feb 1999||27 Mar 2001||Isis Pharmaceuticals, Inc.||Compounds, processes and intermediates for synthesis of mixed backbone oligomeric compounds|
|US6239220||16 Jul 1999||29 May 2001||Isis Pharmaceuticals, Inc.||Recovery of triarylmethyl halide protecting groups cleaved during oligonucleotide synthesis|
|US6274725||23 Oct 1998||14 Aug 2001||Isis Pharmaceuticals, Inc.||Activators for oligonucleotide synthesis|
|US6277334||18 May 1999||21 Aug 2001||Isis Pharmaceuticals, Inc.||Chemical synthesis apparatus employing a droplet generator|
|US6291170||5 Apr 1999||18 Sep 2001||Board Of Trustees Of Leland Stanford University||Multi-genes expression profile|
|US6294664||26 May 1995||25 Sep 2001||Isis Pharmaceuticals, Inc.||Synthesis of oligonucleotides|
|US6326478||8 Jul 1998||4 Dec 2001||Isis Pharmaceuticals, Inc.||Process for the synthesis of oligomeric compounds|
|US6326479||4 Jan 1999||4 Dec 2001||Boston Probes, Inc.||Synthetic polymers and methods, kits or compositions for modulating the solubility of same|
|US6335434||24 Mar 1999||1 Jan 2002||Isis Pharmaceuticals, Inc.,||Nucleosidic and non-nucleosidic folate conjugates|
|US6335437||7 Sep 1998||1 Jan 2002||Isis Pharmaceuticals, Inc.||Methods for the preparation of conjugated oligomers|
|US6335439||11 Jun 1998||1 Jan 2002||Isis Pharmaceuticals, Inc.||Method of preparing phosphoramidites|
|US6399756||8 Jul 1999||4 Jun 2002||Isis Pharmaceuticals, Inc.||Process for the synthesis of oligomeric compounds|
|US6399765||17 Mar 1999||4 Jun 2002||Isis Pharmaceuticals, Inc.||Methods for removing dimethoxytrityl groups from oligonucleotides|
|US6399831||1 Dec 1999||4 Jun 2002||Isis Pharmaceuticals, Inc.||Reagent useful for synthesizing sulfurized oligonucleotide analogs|
|US6403781||8 Jan 2001||11 Jun 2002||Isis Pharmaceuticals, Inc.||Method of synthesizing phosphorothioate oligonucleotides|
|US6414135||7 Jul 1999||2 Jul 2002||Isis Pharmaceuticals, Inc.||C3′-methylene hydrogen phosphonate monomers and related compounds|
|US6440943||14 Jul 1999||27 Aug 2002||Isis Pharmaceuticals, Inc.||Oligonucleotides having site specific chiral phosphorothioate internucleoside linkages|
|US6441161||6 Nov 2000||27 Aug 2002||Gilead Sciences, Inc.||Urea nucleosides as therapeutic and diagnostic agents|
|US6462184||29 Nov 2000||8 Oct 2002||Isis Pharmaceuticals, Inc.||Compounds, processes and intermediates for synthesis of mixed backbone oligomeric compounds|
|US6465628||9 Apr 1999||15 Oct 2002||Isis Pharmaceuticals, Inc.||Process for the synthesis of oligomeric compounds|
|US6476216||18 Oct 1996||5 Nov 2002||Mcgill University||Preparation of phosphorothioate oligomers|
|US6521775||11 Dec 2001||18 Feb 2003||Isis Pharmaceuticals, Inc.||Process for the synthesis of oligomeric compounds|
|US6528631||16 Jun 1998||4 Mar 2003||Isis Pharmaceuticals, Inc.||Oligonucleotide-folate conjugates|
|US6531590||24 Apr 1998||11 Mar 2003||Isis Pharmaceuticals, Inc.||Processes for the synthesis of oligonucleotide compounds|
|US6534639||7 Jul 2000||18 Mar 2003||Isis Pharmaceuticals, Inc.||Guanidinium functionalized oligonucleotides and method/synthesis|
|US6558633||21 Sep 1994||6 May 2003||Isis Pharmaceuticals, Inc.||Chemical reaction apparatus and methods|
|US6593466||7 Jul 1999||15 Jul 2003||Isis Pharmaceuticals, Inc.||Guanidinium functionalized nucleotides and precursors thereof|
|US6596857||1 Dec 1999||22 Jul 2003||Mcgill University||Preparation of phosphorothioate oligomers|
|US6600032||6 Aug 1999||29 Jul 2003||Isis Pharmaceuticals, Inc.||2′-O-aminoethyloxyethyl-modified oligonucleotides|
|US6610837||16 Mar 2000||26 Aug 2003||Isis Pharmaceuticals, Inc.||Phosphate and thiophosphate protecting groups|
|US6610842||6 May 1999||26 Aug 2003||Isis Pharmaceuticals, Inc.||Processes for the synthesis of oligomers using phosphoramidite compositions|
|US6639061||7 Jul 1999||28 Oct 2003||Isis Pharmaceuticals, Inc.||C3′-methylene hydrogen phosphonate oligomers and related compounds|
|US6642373||12 Dec 2002||4 Nov 2003||Isis Pharmaceuticals, Inc.||Activators for oligonucleotide synthesis|
|US6673912||11 Apr 2002||6 Jan 2004||Isis Pharmaceuticals, Inc.||2′-O-aminoethyloxyethyl-modified oligonucleotides|
|US6677471||8 Nov 2002||13 Jan 2004||Isis Pharmaceuticals, Inc.||Intermediates for the synthesis of oligonucleotide analogues|
|US6762298||23 Feb 2001||13 Jul 2004||The United States Of America As Represented By The Department Of Health And Human Services||Thermolabile phosphorus protecting groups, associated intermediates and methods of use|
|US6770442||30 Nov 2001||3 Aug 2004||Boston Probes, Inc.||Methods for modulating the solubility of synthetic polymers|
|US6780989||17 Jan 2003||24 Aug 2004||Isis Pharmaceuticals, Inc.||Diribonucleoside Phosphoramidites|
|US6794502||22 Mar 2002||21 Sep 2004||Isis Pharmaceuticals, Inc.||Methods for removing dimethoxytrityl groups from oligonucleotides|
|US6800751||11 Apr 2002||5 Oct 2004||Isis Pharmaceuticals, Inc.||Reagent and process for protecting nucleoside hydroxyl groups|
|US6818395||6 Nov 2000||16 Nov 2004||California Institute Of Technology||Methods and apparatus for analyzing polynucleotide sequences|
|US6822088||16 Jul 2002||23 Nov 2004||Isis Pharmaceuticals, Inc.||Synthesis of oligonucleotides on solid support|
|US6825338||30 Mar 2001||30 Nov 2004||Isis Pharmaceuticals, Inc.||Labeled oligonucleotides, methods for making same, and compounds useful therefor|
|US6846922||8 Nov 2000||25 Jan 2005||Isis Pharmaceuticals, Inc.||Activators for oligonucleotide synthesis|
|US6861514||9 Oct 2001||1 Mar 2005||Isis Pharmaceuticals, Inc.||Nucleosidic and non-nucleosidic folate conjugates|
|US6861518||24 Sep 2002||1 Mar 2005||Mcgill University||Preparation of phosphorothioate oligomers|
|US6867294||12 Nov 1999||15 Mar 2005||Isis Pharmaceuticals, Inc.||Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages|
|US6911345||18 Jul 2001||28 Jun 2005||California Institute Of Technology||Methods and apparatus for analyzing polynucleotide sequences|
|US6914138||9 Aug 2002||5 Jul 2005||Gilead Sciences, Inc.||Urea nucleosides as therapeutic and diagnostic agents|
|US6919437||10 Jun 1999||19 Jul 2005||Isis Pharmaceuticals, Inc.||Synthetic methods and intermediates for triester oligonucleotides|
|US6965041||16 Feb 2000||15 Nov 2005||The United States Of America As Represented By The Department Of Health And Human Services||N-acylphosphoramidites and their use in oligonucleotide synthesis|
|US6967247||24 Jul 2002||22 Nov 2005||Isis Pharmaceuticals, Inc.||Deprotection of phosphorus in oligonucleotide synthesis|
|US6974865||18 Dec 2002||13 Dec 2005||Isis Pharmaceuticals, Inc.||C3′ -methylene hydrogen phosphonate oligomers and related compounds|
|US7002006||12 Feb 2003||21 Feb 2006||Isis Pharmaceuticals, Inc.||Protection of nucleosides|
|US7030230||25 Oct 2002||18 Apr 2006||Isis Pharmaceuticals, Inc.||Process of purifying phosphoramidites|
|US7041816||20 Jan 2004||9 May 2006||Isis Pharmaceuticals, Inc.||Process for the synthesis of oligomeric compounds|
|US7049102||15 Nov 2000||23 May 2006||Board Of Trustees Of Leland Stanford University||Multi-gene expression profile|
|US7057062||11 Apr 2002||6 Jun 2006||Isis Pharmaceuticals, Inc.||Process for manufacturing purified phosphorodiamidite|
|US7074563||24 Feb 2003||11 Jul 2006||Sequenom, Inc.||Mass spectrometric methods for detecting mutations in a target nucleic acid|
|US7125945||19 Sep 2003||24 Oct 2006||Varian, Inc.||Functionalized polymer for oligonucleotide purification|
|US7169560||24 May 2004||30 Jan 2007||Helicos Biosciences Corporation||Short cycle methods for sequencing polynucleotides|
|US7169916||31 Mar 2003||30 Jan 2007||Isis Pharmaceuticals, Inc.||Chloral-free DCA in oligonucleotide synthesis|
|US7186822||28 Dec 2004||6 Mar 2007||Isis Pharmaceuticals, Inc.||Process for the synthesis of oligomeric compounds|
|US7199236||14 Sep 2004||3 Apr 2007||Isis Pharmaceuticals, Inc.||Process for the synthesis of oligomeric compounds|
|US7220549||30 Dec 2004||22 May 2007||Helicos Biosciences Corporation||Stabilizing a nucleic acid for nucleic acid sequencing|
|US7227016||28 Dec 2004||5 Jun 2007||Isis Pharmaceuticals, Inc.||Process for the synthesis of oligomeric compounds|
|US7227017 *||5 Jun 2003||5 Jun 2007||Avecia Limited||Process for the preparation of phosphorothioate oligonucleotides|
|US7273933 *||26 Feb 1998||25 Sep 2007||Isis Pharmaceuticals, Inc.||Methods for synthesis of oligonucleotides|
|US7276599||2 Jun 2004||2 Oct 2007||Isis Pharmaceuticals, Inc.||Oligonucleotide synthesis with alternative solvents|
|US7297518||12 Mar 2002||20 Nov 2007||California Institute Of Technology||Methods and apparatus for analyzing polynucleotide sequences by asynchronous base extension|
|US7348391||2 Sep 2005||25 Mar 2008||Isis Pharmaceuticals, Inc.||Polymeric beads for oligomer synthesis|
|US7355037||3 Dec 2002||8 Apr 2008||The United States Of America As Represented By The Department Of Health And Human Services||Thermolabile hydroxyl protecting groups and methods of use|
|US7397546||8 Mar 2006||8 Jul 2008||Helicos Biosciences Corporation||Systems and methods for reducing detected intensity non-uniformity in a laser beam|
|US7399845||27 Jan 2007||15 Jul 2008||Isis Pharmaceuticals, Inc.||6-modified bicyclic nucleic acid analogs|
|US7419787||11 May 2006||2 Sep 2008||Sequenom, Inc.||Mass spectrometric methods for detecting mutations in a target nucleic acid|
|US7427675||22 Aug 2005||23 Sep 2008||Isis Pharmaceuticals, Inc.||Compounds and methods for the characterization of oligonucleotides|
|US7462449||14 May 2004||9 Dec 2008||California Institute Of Technology||Methods and apparatuses for analyzing polynucleotide sequences|
|US7476734||6 Dec 2005||13 Jan 2009||Helicos Biosciences Corporation||Nucleotide analogs|
|US7482120||28 Jan 2005||27 Jan 2009||Helicos Biosciences Corporation||Methods and compositions for improving fidelity in a nucleic acid synthesis reaction|
|US7491498||26 Oct 2006||17 Feb 2009||Helicos Biosciences Corporation||Short cycle methods for sequencing polynucleotides|
|US7547684||10 May 2007||16 Jun 2009||Isis Pharmaceuticals, Inc.||5′-modified bicyclic nucleic acid analogs|
|US7569686||10 May 2007||4 Aug 2009||Isis Pharmaceuticals, Inc.||Compounds and methods for synthesis of bicyclic nucleic acid analogs|
|US7635562||25 May 2005||22 Dec 2009||Helicos Biosciences Corporation||Methods and devices for nucleic acid sequence determination|
|US7645596||5 May 2004||12 Jan 2010||Arizona Board Of Regents||Method of determining the nucleotide sequence of oligonucleotides and DNA molecules|
|US7666593||26 Aug 2005||23 Feb 2010||Helicos Biosciences Corporation||Single molecule sequencing of captured nucleic acids|
|US7666854||9 Dec 2008||23 Feb 2010||Isis Pharmaceuticals, Inc.||Bis-modified bicyclic nucleic acid analogs|
|US7695902||20 Feb 2002||13 Apr 2010||Isis Pharmaceuticals, Inc.||Oligoribonucleotides and ribonucleases for cleaving RNA|
|US7700706||17 Dec 2007||20 Apr 2010||Isis Pharmaceuticals, Inc.||Polymeric beads for oligomer synthesis|
|US7741457||29 May 2008||22 Jun 2010||Isis Pharmaceuticals, Inc.||6-modified bicyclic nucleic acid analogs|
|US7750131||19 Mar 2009||6 Jul 2010||Isis Pharmaceuticals, Inc.||5′-modified bicyclic nucleic acid analogs|
|US7759065||22 May 2008||20 Jul 2010||Sequenom, Inc.||Mass spectrometric methods for detecting mutations in a target nucleic acid|
|US7759480||29 Jan 2007||20 Jul 2010||Isis Pharmaceuticals, Inc.||Chloral-free DCA in oligonucleotide synthesis|
|US7812149||4 Nov 2003||12 Oct 2010||Isis Pharmaceuticals, Inc.||2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations|
|US7884086||7 Sep 2005||8 Feb 2011||Isis Pharmaceuticals, Inc.||Conjugates for use in hepatocyte free uptake assays|
|US7897345||13 Feb 2009||1 Mar 2011||Helicos Biosciences Corporation||Short cycle methods for sequencing polynucleotides|
|US7981604||9 Feb 2005||19 Jul 2011||California Institute Of Technology||Methods and kits for analyzing polynucleotide sequences|
|US8022193||5 May 2010||20 Sep 2011||Isis Pharmaceuticals, Inc.||6-modified bicyclic nucleic acid analogs|
|US8030467||31 Mar 2010||4 Oct 2011||Isis Pharmaceuticals, Inc.||5′-modified bicyclic nucleic acid analogs|
|US8088746||14 Jan 2010||3 Jan 2012||Isis Pharmaceuticals, Inc.||Bis-modified bicyclic nucleic acid analogs|
|US8088904||15 Aug 2008||3 Jan 2012||Isis Pharmaceuticals, Inc.||Tetrahydropyran nucleic acid analogs|
|US8138330||11 Sep 2007||20 Mar 2012||Sigma-Aldrich Co. Llc||Process for the synthesis of oligonucleotides|
|US8153602||20 May 1999||10 Apr 2012||Isis Pharmaceuticals, Inc.||Composition and methods for the pulmonary delivery of nucleic acids|
|US8188059||7 May 2007||29 May 2012||Isis Pharmaceuticals, Inc.||Compounds and methods for modulating expression of GCGR|
|US8268980||23 Sep 2011||18 Sep 2012||Isis Pharmaceuticals, Inc.||5′-modified bicyclic nucleic acid analogs|
|US8278283||1 Jul 2008||2 Oct 2012||Isis Pharmaceuticals, Inc.||6-disubstituted or unsaturated bicyclic nucleic acid analogs|
|US8278425||22 May 2008||2 Oct 2012||Isis Pharmaceuticals, Inc.||N-substituted-aminomethylene bridged bicyclic nucleic acid analogs|
|US8278426||6 Jun 2008||2 Oct 2012||Isis Pharmaceuticals, Inc.||Carbocyclic bicyclic nucleic acid analogs|
|US8362232||15 Sep 2010||29 Jan 2013||Isis Pharmaceuticals, Inc.||Compounds and methods for modulating expression of SGLT2|
|US8362234||26 Mar 2007||29 Jan 2013||Archemix Llc||Solid support reagents for synthesis|
|US8372967||7 May 2007||12 Feb 2013||Isis Pharmaceuticals, Inc.||Compounds and methods for modulating expression of GCCR|
|US8394947||3 Mar 2004||12 Mar 2013||Isis Pharmaceuticals, Inc.||Positionally modified siRNA constructs|
|US8426378||19 Mar 2009||23 Apr 2013||Isis Pharmaceuticals, Inc.||Oligomeric compounds comprising tricyclic nucelosides and methods for their use|
|US8440803||1 Dec 2011||14 May 2013||Isis Pharmaceuticals, Inc.||Tetrahydropyran nucleic acid analogs|
|US8501805||23 Sep 2009||6 Aug 2013||Isis Pharmaceuticals, Inc.||Substituted alpha-L-bicyclic nucleosides|
|US8530640||6 Feb 2009||10 Sep 2013||Isis Pharmaceuticals, Inc.||Bicyclic cyclohexitol nucleic acid analogs|
|US8536320||1 Feb 2010||17 Sep 2013||Isis Pharmaceuticals, Inc.||Tetrahydropyran nucleic acid analogs|
|US8546556||21 Nov 2008||1 Oct 2013||Isis Pharmaceuticals, Inc||Carbocyclic alpha-L-bicyclic nucleic acid analogs|
|US8569474||4 Mar 2005||29 Oct 2013||Isis Pharmaceuticals, Inc.||Double stranded constructs comprising one or more short strands hybridized to a longer strand|
|US8604183||4 Nov 2003||10 Dec 2013||Isis Pharmaceuticals, Inc.||Compositions comprising alternating 2′-modified nucleosides for use in gene modulation|
|US8604192||23 Sep 2009||10 Dec 2013||Isis Pharmaceuticals, Inc.||Cyclohexenyl nucleic acids analogs|
|US8636978||15 Jun 2009||28 Jan 2014||The United States Of America, As Represented By The Secretary, Department Of Health And Human Services||Cyclized NGR peptide compounds, compositions, and methods of their use|
|US8673871||7 May 2007||18 Mar 2014||Isis Pharmaceuticals, Inc.||Compounds and methods for modulating expression ApoB|
|US8703728||8 Sep 2004||22 Apr 2014||Isis Pharmaceuticals, Inc.||Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini|
|US8796437||17 Apr 2013||5 Aug 2014||Isis Pharmaceuticals, Inc.||Tetrahydropyran nucleic acid analogs|
|US8883752||23 Oct 2009||11 Nov 2014||Isis Pharmaceuticals, Inc.||5′ and 2′ BIS-substituted nucleosides and oligomeric compounds prepared therefrom|
|US8969316||26 Oct 2012||3 Mar 2015||Isis Pharmaceuticals, Inc.||Compounds and methods for modulating expression of DGAT2|
|US8987435||23 Oct 2009||24 Mar 2015||Isis Pharmaceuticals, Inc.||Oligomeric compounds and methods|
|US8993528||21 Mar 2013||31 Mar 2015||Isis Pharmaceuticals, Inc.||Oligomeric compounds comprising tricyclic nucelosides and methods for their use|
|US8993738||26 Apr 2011||31 Mar 2015||Isis Pharmaceuticals, Inc.||Modified nucleosides, analogs thereof and oligomeric compounds prepared therefrom|
|US9005906||25 Jun 2014||14 Apr 2015||Isis Pharmaceuticals, Inc.||Tetrahydropyran nucleic acid analogs|
|US9012144||18 Jan 2011||21 Apr 2015||Fluidigm Corporation||Short cycle methods for sequencing polynucleotides|
|US9045754||7 May 2007||2 Jun 2015||Isis Pharmaceuticals, Inc.||Short antisense compounds with gapmer configuration|
|US9096636||4 Nov 2003||4 Aug 2015||Isis Pharmaceuticals, Inc.||Chimeric oligomeric compounds and their use in gene modulation|
|US9096898||16 Dec 2010||4 Aug 2015||Life Technologies Corporation||Method of determining the nucleotide sequence of oligonucleotides and DNA molecules|
|US20010028866 *||23 May 2001||11 Oct 2001||Isis Pharmaceuticals, Inc.||Chemical synthesis apparatus employing a droplet generator|
|US20040082774 *||30 Jun 2003||29 Apr 2004||Guzaev Andrei P.||Novel phosphate and thiophosphate protecting groups|
|US20040185491 *||23 Mar 2004||23 Sep 2004||Isis Pharmaceuticals, Inc.||Methods for synthesis of oligonucleotides|
|US20040219577 *||20 Jan 2004||4 Nov 2004||Ravikumar Vasulinga T.||Process for the synthesis of oligomeric compounds|
|US20050020827 *||3 Dec 2002||27 Jan 2005||Beaucage Serge L.||Thermolabile hydroxyl protecting groups and methods of use|
|US20050065290 *||19 Sep 2003||24 Mar 2005||Shah Vipul J.||Novel functionalized polymer for oligonucleotide purification|
|US20050137390 *||28 Dec 2004||23 Jun 2005||Ravikumar Vasulinga T.||Process for the synthesis of oligomeric compounds|
|US20050137391 *||14 Sep 2004||23 Jun 2005||Ravikumar Vasulinga T.||Process for the synthesis of oligomeric compounds|
|US20050182251 *||28 Dec 2004||18 Aug 2005||Ravikumar Vasulinga T.||Process for the synthesis of oligomeric compounds|
|US20060040308 *||22 Aug 2005||23 Feb 2006||Isis Pharmaceuticals, Inc.||Compounds and methods for the characterization of oligonucleotides|
|US20060051800 *||2 Sep 2005||9 Mar 2006||Isis Pharmaceuticals, Inc.||Polymeric beads for oligomer synthesis|
|US20060147942 *||30 Dec 2004||6 Jul 2006||Helicos Biosciences Corporation||Stabilizing a nucleic acid for nucleic acid sequencing|
|USRE39464 *||24 Aug 2004||9 Jan 2007||Isis Pharmaceuticals Inc.||Oligonucleolotides having site specific chiral phosphorothioate internucleoside linkages|
|EP2053406A2||16 Jul 2002||29 Apr 2009||caprotec bioanalytics GmbH||Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions|
|EP2314594A1||27 Jan 2007||27 Apr 2011||Isis Pharmaceuticals, Inc.||6-modified bicyclic nucleic acid analogs|
|EP2332951A2||27 Jan 2007||15 Jun 2011||ISIS Pharmaceuticals, Inc.||6-modified bicyclic nucleic acid analogs|
|EP2708541A1||15 Nov 2004||19 Mar 2014||Isis Pharmaceuticals, Inc.||5,6-dihydroxy-isoindole derivatives as linkers for oligomer solid phase synthesis|
|WO2007134181A2||10 May 2007||22 Nov 2007||Isis Pharmaceuticals Inc||5'-modified bicyclic nucleic acid analogs|
|WO2008150729A2||22 May 2008||11 Dec 2008||Isis Pharmaceuticals Inc||N-substituted-aminomethylene bridged bicyclic nucleic acid analogs|
|WO2010064146A2||2 Dec 2009||10 Jun 2010||Chiralgen, Ltd.||Method for the synthesis of phosphorus atom modified nucleic acids|
|WO2010090969A1||1 Feb 2010||12 Aug 2010||Isis Pharmaceuticals, Inc.||Tetrahydropyran nucleic acid analogs|
|WO2011005860A2||7 Jul 2010||13 Jan 2011||Alnylam Pharmaceuticals, Inc.||5' phosphate mimics|
|WO2011005861A1||7 Jul 2010||13 Jan 2011||Alnylam Pharmaceuticals, Inc.||Oligonucleotide end caps|
|WO2011017521A2||5 Aug 2010||10 Feb 2011||Isis Pharmaceuticals, Inc.||Bicyclic cyclohexose nucleic acid analogs|
|WO2011085102A1||6 Jan 2011||14 Jul 2011||Isis Pharmaceuticals, Inc.||Base modified bicyclic nucleosides and oligomeric compounds prepared therefrom|
|WO2011094580A2||28 Jan 2011||4 Aug 2011||Alnylam Pharmaceuticals, Inc.||Chelated copper for use in the preparation of conjugated oligonucleotides|
|WO2011115818A1||10 Mar 2011||22 Sep 2011||Isis Pharmaceuticals, Inc.||5'-substituted bicyclic nucleosides and oligomeric compounds prepared therefrom|
|WO2011139695A2||26 Apr 2011||10 Nov 2011||Isis Pharmaceuticals, Inc.||Modified 5' diphosphate nucleosides and oligomeric compounds prepared therefrom|
|WO2011139699A2||26 Apr 2011||10 Nov 2011||Isis Pharmaceuticals, Inc.||5' modified nucleosides and oligomeric compounds prepared therefrom|
|WO2011139702A2||26 Apr 2011||10 Nov 2011||Isis Pharmaceuticals, Inc.||Modified nucleosides and oligomeric compounds prepared therefrom|
|WO2011139911A2||29 Apr 2011||10 Nov 2011||Isis Pharmaceuticals, Inc.||Lipid formulated single stranded rna|
|WO2011163121A1||20 Jun 2011||29 Dec 2011||Alnylam Pharmaceuticals, Inc.||Multifunctional copolymers for nucleic acid delivery|
|U.S. Classification||536/25.34, 536/26.5, 536/25.3, 987/189, 536/26.71|
|19 Apr 1993||AS||Assignment|
Owner name: MILLIPORE CORPORATION, MASSACHUSETTS
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNOR:BIOSYNTECH GMBH;REEL/FRAME:006495/0624
Effective date: 19930329
|17 Aug 1993||RR||Request for reexamination filed|
Effective date: 19930701
|17 Feb 1994||AS||Assignment|
Owner name: MILLIPORE INVESTMENT HOLDINGS LTD., DELAWARE
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:MILLIPORE CORPORATION;REEL/FRAME:006862/0716
Effective date: 19931214
|5 Apr 1994||RR||Request for reexamination filed|
Effective date: 19940112
|14 Nov 1994||AS||Assignment|
Owner name: PERSEPTIVE BIOSYSTEMS, INC., MASSACHUSETTS
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:MILLIPORE INVESTMENT HOLDINGS LIMITED;REEL/FRAME:007189/0912
Effective date: 19941102
|29 Nov 1994||RR||Request for reexamination filed|
Effective date: 19940610
|7 Aug 1995||FPAY||Fee payment|
Year of fee payment: 8
|19 Mar 1996||CC||Certificate of correction|
|15 Apr 1998||AS||Assignment|
Owner name: NEXSTAR PHARMACEUTICALS, INC., COLORADO
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:PERSEPTIVE BIOSYSTEMS, INC.;REEL/FRAME:009097/0853
Effective date: 19980122
|9 Sep 1998||AS||Assignment|
Owner name: PROLIGO L.L.C., COLORADO
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:NEXSTAR PHARMACEUTICALS, INC.;REEL/FRAME:009436/0625
Effective date: 19980815
|9 Aug 1999||FPAY||Fee payment|
Year of fee payment: 12